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A B S T R A C T
Weight gain and related metabolic syndrome (MS) are major current issues in public health. MS consists of
abdominal fat, atherogenic dyslipidemia, hypertension, hyperglycemia, insulin resistance, pro-inflammatory and
pro-thrombotic state, and accounts for both cardiovascular diseases and type II diabetes mellitus risk factors.
Patients affected by psychiatric illness present a prevalence of 35–40% of MS. Many studies have shown that
Mediterranean diet is associated with the reduction of mortality due to cardiovascular and malignant diseases,
potentially preventing both obesity and type II diabetes mellitus. Our pilot study explores the effects of a 12-
month healthy lifestyle program (Mediterranean diet and mild physical activity) on metabolic and anthropo-
metric parameters of patients affected by chronic psychiatric disorders who live in a psychiatric community
facility. A Mediterranean diet was provided by a senior nutritional clinician and adapted by two dieticians,
according to the needs and preferences of the community population. Concomitantly, a program of moderate
physical activity, consisting in 30-min walks on level ground 4 days a week, and psycho-educational group
sessions with educational and therapeutic purposes were implemented. The metabolic and anthropometric
parameters of our patients improved after both 6 (T6) and 12 (T12) months. Body Max Index was statistically
significantly reduced at T6 and T12, with patients perceiving good quality of life. These positive outcomes
suggest that a low-cost healthy lifestyle program can produce good adherence and feasibility even among pa-
tients with chronic psychiatric diseases, reducing their risk for MS, cardiovascular diseases and other compli-
cations.
1. Introduction
Weight gain and related metabolic syndrome (MS) are major recent
issues in public health. The main components of MS are abdominal fat,
atherogenic dyslipidemia, hypertension, hyperglycemia, insulin re-
sistance, pro-inflammatory and pro-thrombotic state, accounting for
both cardiovascular diseases and type II diabetes mellitus risk factors
(Grundy et al., 2004). Patients affected by psychiatric illness present an
increased risk for MS if compared with the general population, showing
a MS prevalence of 35–40%, further increased in female gender
(McEvoy et al., 2005). In particular, the prevalence of obesity, with an
unfavorable ratio of lean and fat mass (Saarni et al., 2009), is almost
doubled among patients affected by psychiatric illness compared to the
general population (Allison et al., 2009). Although the causes that may
increase MS prevalence among patients with chronic psychiatric dis-
order are not fully known, many risk factors are indicated: altered
lifestyle habits induced by psychiatric disorders, high-fat diets, glucose
and lipid metabolism alteration induced by antipsychotics, a genetic
tendency to accumulate intra-abdominal fat, poor glucose control
(Chaggar et al., 2011), hypercortisolemia and related central obesity
induced by hypothalamic pituitary abnormalities. This high prevalence
of MS is responsible for organic co-morbidities and premature death
among patients affected by psychiatric disorders, who present an
average life expectancy decreased by 20% (Kilbourne et al., 2009;
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Hennekens, 2007). One of the most important strategies aimed at re-
ducing cardiovascular and diabetics risk consists of an early lifestyle
modification through a balanced diet and increased physical activity
(Rosenbaum et al., 2014). This strategy combined with or without
pharmacological therapy (statins and oral hypoglicemic agents) re-
mains the main goal of primary intervention (Halcox and Misra, 2015).
Lifestyle changes can be easily implemented in different cultural and
social backgrounds, representing a primary cost-effective intervention
in MS prevention. Nevertheless, this approach does not appear feasible
in patients with chronic mental illness, who often show low therapeutic
compliance (Ratliff et al., 2012), since self-determination in changing
lifestyle is necessary (Vancampfort et al., 2013). In particular, it is es-
sential that patients with MS be aware of the benefits gained from
lifestyle modification, not only to significantly decrease cardiovascular
risks but also to improve their perceived well-being and quality of life
(Lin et al., 2014; Kolotkin et al., 2008; Lakka and Laaksonen, 2007).
Prospective studies and clinical trials have shown that the Mediterra-
nean diet is associated with a reduction in MS risk factors, preventing
increases of waist circumference, systolic and diastolic pressure and
sugar, triglyceride and LDL cholesterol blood levels (Kastorini et al.,
2011). Mediterranean diet is positively related to health improvement
in terms of mortality reduction from cardiovascular and malignant
diseases, preventing both obesity and type II diabetes mellitus (Babio
et al., 2014).
2. Aims
To evaluate the association of Mediterranean diet and mild physical
activity on metabolic and anthropometric parameters, and, con-
comitantly, on quality of life and global functioning of patients with
chronic psychiatric illness, residents in a socio-rehabilitative commu-
nity.
3. Methods
The current pilot study explores the effectiveness of a healthy life-
style program (Mediterranean diet and mild physical activity) over a
12 month period for improving metabolic and anthropometric para-
meters in patients affected by chronic psychiatric disorders who live in
a psychiatric community facility. It represented an intervention aimed
at raising awareness for a healthy lifestyle among patients and staff of a
community where no other similar programs had ever been im-
plemented previously. This study was approved by the Local Ethical
Committee (Prot. 4458) and was conducted over a 1-year period (01/
04/2015–1/4/2016).
A Mediterranean diet, which represents a proper nutritional edu-
cational model in accordance with the literature (Willett et al., 1995),
was provided by a senior nutritional clinician and adapted by two
dieticians according to the needs and preferences of community po-
pulation. The daily diet included proteins (17%), fats (28%), carbohy-
drates (55%), cholesterol (152 mg/day), fibres (38 g/day) and con-
sisted of fresh vegetables and fruits, beans, nuts, grains and seeds, olive
oil as a main source of fats, cheese and yogurt, small amounts of fish
and poultry, very small amounts of red meat per week. A percentage of
between 25 and 35% of energy source intake was represented by fats, of
which only 7% saturated ones. In our study, dietary intake normally
consisted in 3 main meals and two snacks provided by the community.
Additional food was available and could be purchased by patients at the
community café. Only occasionally did patients spend meal time out-
side the community with their family and friends. The integrated in-
dexes of nutritional assessment were analysed to assess the possible risk
of the subjects' malnutrition during the study period. Concomitantly, a
program of moderate physical activity was implemented: walking on
level ground supervised by the community professionals for 30 min a
day, 4 days a week. Psycho-educational group sessions conducted by
the two dieticians were implemented with double aims: educational (in
terms of nutrition) and therapeutic (in terms of motivation and re-
lationship with others). These psycho-educational groups met bi-
monthly for the first three months, then monthly for the remaining
period of the study. In addition, the professionals and the cook working
in the community and the co-investigators of this study also partici-
pated in group management. The dieticians, during the psycho-educa-
tional groups, motivated patients to reduce extra-meal food consump-
tion and involved them in changing their lifestyle. In particular, they
suggested that patients rearrange the community café, reducing the
availability of most caloric foods, the quantity of food displayed on the
shelves, etc.
The sample for this pilot study was collected according to our se-
lection criteria. Inclusion criteria: all patients living in the community
during the study period affected by chronic and severe psychiatric
diseases and treated with multiple anti-psychotic drugs; they also suf-
fered from organic diseases treated with cardiovascular and metabolic
medicines. Exclusion criteria: patients with special dietary needs due to
severe organic diseases and patients unable to give a valid and informed
consent.
The community where the program was implemented is a psy-
chiatric facility with a maximum of 19 patients who need rehabilitative
programs in a residential setting for a long period of time (on average
18 months). The community is managed by 9 professionals in re-
habilitative programs, two nurses and a cook, who prepares meals in
the community kitchen. Medical and psychiatric treatment is provided
by the general practitioner and each Patient's Mental Health Service
psychiatrist. Many volunteers and the Patients themselves participate in
all rehabilitative activities normally aimed at developing their daily life
skills.
For each patient the following variables were selected:




• years of psychiatric illness
• substance abuse comorbidity
• psychiatric drug therapy
• number of admissions in the observation year
3. Organic variables:
• blood pressure, heart rate and ECG
• Body Max Index (BMI), waist circumference
• total cholesterol, LDL, HDL, triglycerides, blood glucose, uric acid,
homocysteine and TSH reflex
• cardiovascular and metabolic therapy.
The mentioned data were collected from patient medical records
and Department Health Service clinical information systems and were
reported in an Excel database. Additional information was obtained
from the psychiatrists who treated the patients.
The following tests were administered to the patients:
• Global Assessment Functioning (GAF), (Rush et al., 2008) at T0 and
T6.
• Brief Psychiatric Rating Scale (BPRS) (Overall and Gorham, 1962) at
T0 and T6.
• EuroQuol-5D (EQ-5D) at T6 and T12 (Brooks et al., 2010).
3.1. Statistical analysis
The descriptive statistical analysis and comparison of endpoints
between T0, T6 and T12 (mean ± standard deviation, paired t-test for
continuous variables; percentages and Chi2 test for categorical vari-
ables) were carried out.
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4. Results
Our Patients, as shown in Table 1, were affected by severe and
chronic psychiatric disorders which had required many previous hos-
pitalizations (some of them were also hospitalized in the psychiatric
asylum before its closure in 1978). All Patients were single and earned
invalidity benefits. Most of them (89.5%) suffered from one (or more
than one) organic disease in comorbidity, treated with multiple drug
therapy. Probably due to their life maladjustment conditions, social
isolation and severity of their illnesses, they had required admission to
the community facility where they lived at the moment of the research.
During the course of this study, our population, initially composed of 19
subjects, was reduced to 11 subjects at T12 because two patients died
and others were transferred or discharged. At T0, our patients presented
a mean BMI of 29.14 ± 7.03, indicating overweight condition, that
showed a statistically significant reduction at T6 and T12 (Table 2). The
waist circumference remained almost unchanged at T6 and T12
whereas all metabolic parameters improved either at T6 and/or T12,
although without any statistically significant difference. Vital
parameters, blood pressure, heart rate and ECG remained within the
normal ranges during the period of the study. The EQ-5D score at T6
and T12 showed a positive perception of life quality; GAF and BRIEF
scores remained unchanged at T6 (Table 2). In Table 2, it has been
reported paired t-test between the parameters of the 15 no dropout
patients at T6 vs T0 and between the parameters of the 11 no dropout
patients at T12 vs T0 and T6. The psychopharmacology and organic
therapy remained almost unchanged at T12 in comparison with the
therapies prescribed at T0 (Table 1). During the period of study, two
patients needed to be hospitalized in a psychiatric ward for a short
period.
5. Discussion
The current pilot study demonstrated good adherence and feasi-
bility. Our Patients appreciated the healthy lifestyle implemented by
Mediterranean diet and mild physical activity and quite regularly par-
ticipated in the group educational sessions. Overall, metabolic and
anthropometric parameters showed a satisfactory improvement.
Although we cannot easily separate out the potential impact of exercise
from that of the diet, we can infer that Mediterranean diet, more strictly
implemented than physical activity, had more contributed to this result.
Patients' quality of life remained stable over time as did their global
functioning and psychiatric symptoms. In our experience, both patients
and health professionals found this program helpful in practicing
healthy attitudes for improved physical and psychological conditions.
At the beginning, the implementation of this program represented a
challenge due to the severe and chronic conditions of our patients and
the skepticism of the community professionals, but, with its progress, it
permitted to both parties to share rehabilitative activities, providing
increased satisfaction. These positive outcomes suggest that a low-cost
program consisting of diet and moderate physical activity can also be
implemented in a psychiatric community for patients affected by
chronic psychiatric diseases, reducing the risk for MS, cardiovascular
diseases and other complications. The principle limitation of our pilot
study is represented by its small number of subjects, no sufficient to
draw any conclusions. Moreover, since this intervention was the first
healthy lifestyle program implemented in the community, it is not
possible to compare our results with previous ones.
6. Conclusion
Patients affected by psychiatric illness present an increased risk for
MS and premature death if compared with the general population. This
pilot study showed that implementing a low impact lifestyle change can
improve anthropometric and metabolic outcomes and therefore po-
tentially decreases risk for MS, with good patients' perceived quality of
life. As mental health professionals we have to care for patients by
adopting a holistic approach which also focuses on physical health care.
A healthy lifestyle program can represent a desirable ethical approach
for patients with multiple comorbidities and therapies living in a
community. A multi-professional team is essential for the im-
plementation of a lifestyle modification in order to tailor therapeutic
intervention and to meet patients' needs. We hope that similar programs
can be applied in other facilities to verify their applicability and effi-
cacy in preventing the important health issue of metabolic syndrome
and its complications.
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Table 1
Demographic and clinical characteristic of our Patients at T0 (n = 19).
Demographic and clinical characteristics of our population
Age m ± SD







Intermediate school 15 (79%)
High School 3 (16%)
Degree 1(5%)
Marital status n (%)
Single 19 (100%)
Psychiatric Diagnosis (ICD-9-CM) n (%)
Schizophrenic Disorders 9 (47%)
Personality Disorders 4 (21%)
Bipolar Disorders 3 (16%)
Mental Retardation 3 (16%)
Psychiatric comorbidity (ICD-9-CM) n (%)
Substance Abuse 3 (16%)
Mental Retardation 3 (16%)
Organic Comorbidity (ICD-9-CM) n (%)
Patients affected by an organic disease 17 (89%)
Organic comorbidities n (%)
Metabolic Syndrome 10 (53%)
Anaemia 3 (16%)
Chronic obstructive pulmonary disease (COPD) 3 (16%)
Cholethiasis 3 (16%)
Arthrosis 3 (16%)
Parkinson syndrome and epilepsy 3 (16%)
Cancer 2 (10%)
Period of psychiatric treatment n (%)
Patients> 10 years for all patients 19 (100%)
Pharmacological therapy n (%)







Other drug therapies n (%)
Patients treated with other drugs 16 (84%)
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Table 2









BMI, m ± SD 29.14 ± 7.03 27.75 ± 6.47* 26.69 ± 6.72** *vs BMI at T0 of 15 patients:
t = 4.93, p = 0.0002, t-test paired
**vs BMI at T0 of 11 patients: t = 2.49, p = 0.03, t-test paired
Waist circumference (cm), m ± SD 105.93 ± 13.74 104.66 ± 15.24 105 ± 12.14 t-test paired
Not statistically significant
Glucose mg/dl, m ± SD 78.26 ± 26 84 ± 24.96 82 ± 18.12 t-test paired
Not statistically significant
Homocysteine umoli/l, m ± SD 16.01 ± 5.34 14.70 ± 6.95 14.90 ± 8.79 t-test paired
Not statistically significant
Total cholesterol mg/dl, m ± SD 203.33 ± 47.92 209.8 ± 44.96 190.27 ± 56.04 t-test paired
Not statistically significant
HDL cholesterol mg/dl, 51.06 ± 11.53 50.4 ± 14.69 54.91 ± 11.77 t-test paired
Not statistically significant
Triglycerides mg/dl, m ± SD 141.26 ± 58.51 144.2 ± 61.06 114.73 ± 58.49 t-test paired
Not statistically significant
TSH 1.89 ± 0 0.71 1.91 ± 0.73 1.65 ± 0.56 t-test paired
Not statistically significant
Uric acid 5.23 ± 1.05 5.12 ± 0.95 – t-test paired
Not statistically significant













ECG (QTc, m ± SD) 0.422 ± 0.007 0.417 ± 0.02 0.412 ± 0.03 t-test paired
Not statistically significant
EQ-5D, m ± SD – 80.41 ± 16.30 75.33 ± 17.44 t-test paired
Not statistically significant
GAF 32.55 ± 9.85 33.86 ± 12.66 – t-test paired
Not statistically significant
BPRS 23.53 ± 9.24 23 ± 8.75 – t-test paired
Not statistically significant
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